替比夫定联合扶正化瘀胶囊治疗慢性乙型肝炎纤维化临床观察

目的：观察替比夫定联合扶正化瘀胶囊治疗慢性乙型病毒性肝炎纤维化的疗效。方法：将60例乙型病毒性肝炎患者（存在肝纤维化）随机分为治疗组和对照组。治疗组采用替比夫定和扶正化瘀胶囊治疗；对照组采用替比夫定治疗，疗程均为48周。观察两组治疗前后疗效、肝功、肝纤维化指标、B超指标及DNA定量变化。结果：治疗组治疗后肝功能及肝纤维化指标（HA、Ⅳ-C）均有所改善（P〈0.05）；脾脏厚度明显缩小（P〈0.05），门静脉和脾静脉内径较对照组缩小，但无统计学意义（P〉0.05）；治疗后治疗组HBV-DNA转阴率为46%，E抗原转换率为38%，对照组分别为41%、36%，治疗组上述指标略高于对照组，但无统计学意义（P〉0.05）。结论：替比夫定联合扶正化瘀胶囊治疗，能够通过抑制病毒和抗纤维化，明显改善乙型病毒性肝炎纤维化患者的病情和预后。

Effect of Telbivudine Combined with Fuzhenghuayu Capsule on the Treatment of Chronic Hepatitis B and Liver Fibrosis

Objective：To observe the effect of telbivudine combined with Fuzhenghuayu capsule on the treatment of chronic hepatitis B and liver fibrosis. Method：60 cases of patients with hepatitis B virus（accompanied with fibrosis）were randomly divided into treatment group and control group. The treatment group were treated with telbivudine and Fuzhenghuayu capsule,the control group were treated with telbivudine therapy. The course of the treatment continued for 48 weeks. The symptoms,signs,liver function,hepatic fibrosis index,DNA index and quantitative change of B ultrasound of patients in two groups were observed and compared before and after treatment. Result：Treatment group after treatment of liver function and liver fibrosis index（HA,Ⅳ-C）were improved（P〈0.05）;Thickness of spleen significant reduction（P〈0.05）,portal vein and splenic vein diameter was smaller, but without statistical significance（P〉0.05）;Treatment group after treatment of HBV-DNA overcast rate was 46%,E antigen conversion rate was 38%,the control group were 41%,36%,the index of the treatment group slightly higher than the control group,but no statistical significance（P〉0.05）. Conclusion：Telbivudine combined with Fuzhenghuayu capsule can suppress the virus and anti fibrosis,significantly improve condition and prognosis of patients with hepatitis B fibrosis.